TrialThe Lancet. Infectious diseases2022

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.

Saranya Sridhar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.